AI-Powered Blood Test Accurately Classifies Multiple Neurodegenerative Diseases And Detects Co-Existing Conditions

Neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), frontotemporal dementia, and other related conditions, currently affect over 57 million people worldwide. Addressing this growing global health challenge clearly requires precise diagnostic methods. A study recently published in Alzheimer’s & Dementia (the journal of the Alzheimer’s Association) details an important advancement in neurological diagnostics. Researchers from the Washington University School of Medicine in St. Louis (WashU Medicine) developed an artificial intelligence (AI) classifier capable of distinguishing among several major neurodegenerative diseases. By analyzing 15 specific proteins from a standard blood draw, this tool separates Alzheimer’s disease, Parkinson’s disease, frontotemporal dementia, and dementia with Lewy bodies from each other and from normal cognitive aging.

The classifier, dubbed “GPND-AI” (Generalizable Protein-based Neurodegenerative Disease Artificial Intelligence), demonstrated a diagnostic accuracy rate of over 90%. This innovative test can also detect when a patient is affected by several disease processes at once, allowing clinicians to pinpoint the exact neurodegenerative pathways involved by identifying early biological markers. These types of integrations lead to better patient outcomes and increased clinical certainty.

Overcoming Diagnostic Ambiguity In Neurology

Diagnosing neurodegenerative diseases correctly remains a significant challenge in modern medical practice. Patients exhibiting signs of cognitive decline often navigate a time and money-consuming clinical journey full of uncertainties. Additionally, in many cases, symptoms of different dementias overlap significantly, making clinical evaluations subjective and prone to human error. Consequently, physicians struggle to determine whether a patient has Alzheimer’s disease or another form of dementia based solely on memory tests, motor function evaluations, and behavioral assessments. 

While invasive procedures such as lumbar punctures or expensive imaging scans (MRI or PET) offer clarity, these methods remain inaccessible for many patients due to high systemic costs and limited regional availability. Rural populations and individuals without comprehensive health insurance often face significant financial and geographical barriers when seeking specialized neurological evaluations. As a result, many individuals miss out on a precise diagnosis during the early stages of cognitive decline, thereby losing the optimal window for early intervention.

This widespread diagnostic ambiguity hinders effective patient care and complicates family planning. Without knowing the exact biological mechanisms driving cognitive decline, medical professionals cannot prescribe the most appropriate treatments or lifestyle changes. In addition, misdiagnoses often lead to side effects from incorrect medications and cause emotional distress for patients and caregivers. 

Recognizing the urgent need for an accessible and objective diagnostic alternative, the WashU Medicine research group aimed to bridge this gap by developing a non-invasive tool capable of reflecting the biological complexity of the aging brain. They hypothesized that analyzing blood plasma could democratize expert-level neurological diagnostics across diverse medical settings, reducing the traditional dependence on specialized neurology clinics and expensive imaging infrastructure.

Decoding The 15-Protein Biomarker Panel

To build this diagnostic tool, the WashU Medicine researchers analyzed proteomic and clinical information. They sourced reference data from the Charles F. and Joanne Knight Alzheimer’s Disease Research Center and the Movement Disorder Clinic to train and test their AI classifier. Utilizing the NUcleic acid-Linked Immuno-Sandwich Assay (NULISA) central nervous system (CNS) panel, the team examined thousands of circulating proteins in human blood. This assay technology allows for the high-sensitivity detection of low-abundance proteins in plasma. Through rigorous machine learning protocols, the scientists narrowed down the molecular candidates to a core set of 15 informative proteins. These selected biomarkers reflect key elements of neurodegenerative pathology, including synapse damage, nerve deterioration, and brain inflammation. This targeted proteomics approach ensures the test captures the most vital physiological indicators of disease progression without requiring excessive computational power to analyze irrelevant data points.

The resulting GPND-AI classifier achieved notable performance metrics during its initial trials. During the testing phase, the 15-protein panel reached an area under the ROC curve of 0.955 and a 92.3% accuracy rate across five distinct diagnostic categories. To ensure the reliability of their findings, the researchers performed external validation using a separate cohort from the Banner Sun Health Research Institute. The tool matched its initial success, proving that the algorithm could generalize accurately across different patient populations. Importantly, the classifier outputs aligned closely with the actual pathological burden discovered in brain tissue upon autopsy, securely cementing the biological validity of the blood test.

Disentangling Complex Mixed Pathologies

A distinct capability of this new AI diagnostic tool lies in its ability to detect mixed pathologies. In everyday clinical settings, older patients frequently develop overlapping neurodegenerative conditions at the same time. For instance, a person might show outward symptoms of Parkinson’s disease but simultaneously harbor Alzheimer’s disease pathology within their brain tissue. Traditional frameworks force patients into a single disease category, ignoring secondary biological processes at play. This oversimplification renders standard treatments ineffective and confuses the results of clinical trials. One example is that a patient misdiagnosed with pure Alzheimer’s disease might receive medications that fail to address their underlying Lewy body pathology, leading to continued cognitive decline despite strict treatment adherence.

According to Dr. Carlos Cruchaga, the senior author of the study and the Barbara Burton and Reuben M. Morriss III Professor in the Department of Psychiatry at WashU Medicine, “many patients get labeled with a single diagnosis of, say, Alzheimer’s or Parkinson’s, but in reality their brains often show a mixture of disease injuries”. He also explained that existing medical tools lacked the specific design necessary to capture this intricate biological overlap. “Our goal was to build a test that doesn’t just say ‘yes’ or ‘no’ to one disease but instead gives an indication of all the major neurodegenerative diseases happening in that person”, stressed Cruchaga.

Transforming Clinical Trials And Precision Medicine

The ability to map co-existing neurodegenerative processes opens new possibilities for precision medicine in neurology. When physicians can identify the exact combination of protein biomarkers in a patient’s blood, they can tailor clinical interventions to those specific biological drivers. In case a patient shows early biological changes associated with both Alzheimer’s disease and Lewy body dementia, they can also adjust therapeutic strategies accordingly. This level of biological insight prevents the prescription of drugs that might accidentally exacerbate secondary conditions and helps neurological specialists anticipate how a patient’s symptoms might evolve. This proactive approach alters the current reactive paradigm of dementia care, allowing medical professionals to stay ahead of the disease progression before irreversible neurological damage occurs.

Beyond individual patient care, this blood-based classifier will accelerate biopharma research and drug development. Clinical trials testing new neurodegenerative therapies currently experience high failure rates, partially due to poor patient selection criteria. If a trial tests a drug designed to clear amyloid plaques, but a large portion of participants have frontotemporal dementia instead of Alzheimer’s, the trial data will skew negatively and hide potential drug efficacy. The new AI tool allows clinical researchers to screen and enroll the right patients for specific disease pathways using a simple blood draw. Moreover, implementing this technology could save the healthcare system millions of dollars by eliminating the need for redundant and expensive diagnostic imaging procedures during trial screening phases.

Moving Toward Future Clinical Applications

While this 15-protein blood test represents a scientific advancement, the underlying technology requires further refinement before commercial release. Medical researchers must conduct additional prospective longitudinal studies to standardize the blood testing protocols and secure regulatory approvals.

Nevertheless, the foundational evidence provided by the WashU Medicine team proves the utility of proteomics-based approaches for complex dementia diagnostics. In the near future, this accessible blood test could become a routine part of senior healthcare. Ultimately, providing precise and early diagnoses through a simple blood draw will empower patients, guide specialized care, and accelerate the discovery of targeted therapies for brain disorders. 

Author

Richard Chau